Latest Health News

Findi Limited has voluntarily suspended trading of its shares pending an announcement on its ongoing strategic review and financing discussions, delaying the FY26 audited financial statements beyond the June 30 deadline.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.

SGH Ltd has greenlit a $500 million on-market share buy-back, signalling confidence in its financial position following improved leverage and cash flow. The program aims to balance shareholder returns with ongoing investment and growth ambitions.

Lindian Resources reports strong construction and mining readiness progress at Kangankunde, maintaining its timeline for first production in late 2026 while advancing a major expansion study.

GPT Group has declared an estimated 12.25 cents per stapled security distribution for the first half of 2026, marking a modest increase from prior payouts as it prepares to release interim financial results in August.

CONNEQT Health has raised A$5.5 million through a two-tranche placement at a 15.4% discount, backed by key shareholders, to accelerate its commercial expansion and product development.

Holista Colltech's joint venture Ovicoll has acquired industrial land in Collie to build a modular sheep collagen production plant, aiming for operation by December 2026.

Aguia Resources has rapidly converted its Pampafós phosphate fertiliser project into commercial sales, securing AUD 600,000 in revenue within 14 days, anchored by a 2,000-tonne contract with a leading Brazilian agricultural cooperative.

Meteoric Resources has secured key federal endorsements for its Caldeira Rare Earth Project’s environmental licensing, keeping the Installation License on schedule for December 2026 and paving the way for a final investment decision.

RLF AgTech has revamped its executive remuneration to tie CEO incentives directly to share price hurdles, revenue growth, and operating cash flow, reinforcing its focus on sustainable profitability.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.